Get the Stockscreener App
1.265
1.94%
-0.025
Femasys Inc stock is traded at $1.265, with a volume of 58,463.
It is down -1.94% in the last 24 hours and down -17.86% over the past month.
See More
Previous Close:
$1.29
Open:
$1.25
24h Volume:
58,463
Relative Volume:
0.15
Market Cap:
$33.75M
Revenue:
$950.10K
Net Income/Loss:
$-16.69M
P/E Ratio:
-1.5241
EPS:
-0.83
Net Cash Flow:
$-15.16M
1W Performance:
-5.24%
1M Performance:
-17.86%
6M Performance:
+13.45%
1Y Performance:
-30.11%
1-Day Range:
$1.22
$1.30
1-Week Range:
$1.1801
$1.39
52-Week Range:
$0.86
$1.84
Femasys Inc Stock (FEMY) Company Profile
Name
Femasys Inc
Sector
Industry
Phone
770-500-3910
Address
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
1.25 | 33.75M | 950.10K | -16.69M | -15.16M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
496.92 | 176.91B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
222.04 | 66.11B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
91.86 | 45.71B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
213.24 | 31.36B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
31.86 | 16.40B | 17.28B | 108.00M | 391.00M | 0.20 |
Femasys Inc Stock (FEMY) Latest News
Femasys Reports Wider-Than-Expected Annual Loss, But Retail Continues To Be Optimistic - Asianet Newsable
HC Wainwright Reaffirms “Buy” Rating for Femasys (NASDAQ:FEMY) - Defense World
Femasys Positioned for Growth with Innovative Products and Strategic Partnerships - TipRanks
H.C. Wainwright maintains Femasys stock Buy rating, $15 target - Investing.com India
H.C. Wainwright maintains Femasys stock Buy rating, $15 target By Investing.com - Investing.com Australia
Femasys earnings missed by $0.04, revenue fell short of estimates - Investing.com Canada
Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Femasys reports FY24 EPS (85c), consensus (81c) - TipRanks
Femasys Inc. FY EPS USD -0.85 - Marketscreener.com
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update - GlobeNewswire
FEMASYS Earnings Preview: Recent $FEMY Insider Trading, Hedge Fund Activity, and More - Nasdaq
FY2026 Earnings Forecast for Femasys Issued By HC Wainwright - Defense World
HC Wainwright Boosts Femasys (NASDAQ:FEMY) Price Target to $15.00 - Defense World
H.C. Wainwright raises Femasys stock price target to $15 By Investing.com - Investing.com Australia
Femasys price target raised to $15 from $12 at H.C. Wainwright - Yahoo Finance
H.C. Wainwright raises Femasys stock price target to $15 - Investing.com
Femasys (FEMY) to Release Earnings on Thursday - Defense World
Femasys Gains Momentum with EU Approval and Strategic Partnerships, Boosting Buy Rating - TipRanks
Femasys Announces Partnership with CNY Fertility, National - GlobeNewswire
Femasys Secures Game-Changing Partnership: FemaSeed Now Available at 11 Leading Fertility Centers - StockTitan
Femasys’s Strategic Expansion and Promising Clinical Results Justify Buy Rating - TipRanks
Assessing Femasys: Insights From 4 Financial Analysts - Benzinga
Femasys Signs FemBloc Commercial Distribution Deals -March 18, 2025 at 09:58 am EDT - Marketscreener.com
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain - GlobeNewswire
Femasys Breaks Into European Market: First Global Deal for Revolutionary Birth Control Solution - StockTitan
HC Wainwright Reiterates “Buy” Rating for Femasys (NASDAQ:FEMY) - Defense World
H.C. Wainwright maintains Femasys stock Buy rating, $12 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Femasys stock Buy rating, $12 target - Investing.com
Femasys gains CE mark for non-surgical birth control system By Investing.com - Investing.com Australia
Femasys Achieves CE Mark for FemBloc, Paving the Way for European Market Entry and Justifying Buy Rating - TipRanks
Femasys Receives CE Mark for FemBloc Non-Surgical Permanent Birth Control System - Femtech Insider
Femasys gains CE mark for non-surgical birth control system - Investing.com
Femasys Announces FemBloc Delivery System Approval in - GlobeNewswire
Revolutionary Breakthrough: Femasys Gets EU Approval for Non-Surgical Permanent Birth Control - StockTitan
Femasys announces FemBloc delivery system approval in Europe - TipRanks
Femasys Offers a Fresh Take on Women’s Reproductive Healthcare - MD+DI
Femasys gains UK approval for women's health products - MSN
Femasys’s FemBloc: A Promising Investment in Permanent Contraceptive Innovation - TipRanks
Femasys announces publication of ‘positive’ results from FemBloc trials - TipRanks
Femasys Announces Peer-Reviewed Publication of Positive - GlobeNewswire
Could This Non-Surgical Birth Control Method Replace Traditional Sterilization? Clinical Trials Say Yes - StockTitan
Femasys Inc Stock (FEMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
2.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):